Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-017-1519-8
Abstract: The effectiveness and safety of apixaban for stroke prevention in atrial fibrillation (SPAF) demonstrated in ARISTOTLE needs to be confirmed in daily care. To evaluate effectiveness and safety of apixaban therapy in SPAF patients in… read more here.
Keywords: 100 patient; patient years; safety apixaban; daily care ... See more keywords
EFFECTIVENESS AND SAFETY OF APIXABAN VERSUS WARFARIN IN OBESE PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION ENROLLED IN MEDICARE AND VETERAN AFFAIRS
Sign Up to like & getrecommendations! Published in 2021 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(21)02950-8
Abstract: Methods: This retrospective study used body weight data ≥100kg or body mass index (BMI) ≥30 to identify NVAF patients with obesity among dually enrolled Veterans Affairs (VA) and fee-for-service (FFS) Medicare patients. It evaluated risk… read more here.
Keywords: safety apixaban; obese patients; effectiveness safety; apixaban versus ... See more keywords
Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference?
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Haematology"
DOI: 10.1111/ejh.13599
Abstract: Data on the safety of apixaban compared to warfarin in hemodialysis (HD) patients are accumulating, but the impact of concomitant antiplatelet use is unknown. read more here.
Keywords: apixaban compared; warfarin hemodialysis; compared warfarin; safety apixaban ... See more keywords